U.S. Transdermal Drug Delivery System Market Worth $71.63 Billion By 2030

U.S. Transdermal Drug Delivery System Market Growth & Trends

The U.S. transdermal drug delivery system market size is projected to reach USD 71.63 billion by 2030, expanding at a CAGR of 11.4% over the forecast period, according to a study by Grand View Research, Inc. Growing awareness about non-invasive administration and rising demand for painless delivery of drugs is the major factor driving the demand for transdermal drug delivery systems in the U.S.

Incorporation of the transdermal drug delivery system also promotes self-reliance in patients and results in a significant reduction in the frequency of hospital visits, which in turn reduces the overall treatment cost. Moreover, it also makes it very convenient for the patients to administer medications on time without any help. Furthermore, consistent technological advancements, the presence of major market players, and high funding by the government in R&D represent favorable growth for the market in the U.S.

The COVID-19 pandemic had a moderately negative impact on the transdermal drug delivery system market. While most markets struggled to make revenues in line with the pre-COVID years, the U.S. transdermal drug delivery market managed to generate it. However, there was a drop in the overall growth rate, which the market quickly recovered in the second half of the pandemic.

Continuous research to expand the usage of transdermal drug delivery systems across different applications is expected to propel the growth of the market. In addition, consistent efforts by the key players to introduce new products in the market that will serve as a better alternative to conventional drug delivery systems represent lucrative growth opportunities.

 Request a free sample copy or view report summary: U.S. Transdermal Drug Delivery System Market Report

U.S. Transdermal Drug Delivery System Market Report Highlights

• Based on technology, the iontophoresis segment dominated the market in 2022 due to its advantages while administering drugs non-invasively

• The mechanical arrays technology segment is expected to generate maximum growth due to increasing usage in aesthetics and the launch of new products

• Based on application, the pain management segment held the highest market share in 2022 due to increasing demand for these systems in pain management

• The cardiovascular application segment is expected to experience the fastest growth over the forecast period due to effective results while using these devices in the treatment of cardiovascular diseases

• The presence of major players and the availability of technologically advanced products is expected to lead to the continuous growth of the market in the U.S.

U.S. Transdermal Drug Delivery System Market Segmentation

Grand View Research has segmented the U.S. transdermal drug delivery system market based on technology, application, and country:

U.S. Transdermal Drug Delivery System Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Electroporation

• Radio Frequency

• Iontophoresis

• Microporation

• Thermal

• Mechanical arrays

• Ultrasound

• Others

U.S. Transdermal Drug Delivery System Application Outlook (Revenue in USD Billion, 2018 - 2030)

• CNS

• Pain Management

• Cardiovascular

• Hormone

• Immunological

• Metabolic

• Gastrointestinal

• Infection

• Cancer

• Others

  • Urological

  • Blood disorders

  • Respiratory

  • Musculoskeletal

U.S. Transdermal Drug Delivery System Country Outlook (Revenue, USD Billion, 2018 - 2030)

• U.S.

List of Key Players in the U.S. Transdermal Drug Delivery System Market

• Novartis AG

• Johnson & Johnson

• Viatris Inc.

• Boehringer Ingelheim GmbH

• Biogel Technology, Inc.

• 3M Company

• Noven Pharmaceuticals, Inc.

• Nutriband Inc.

• Transdermal Corporation

• Echo Therapeutics, Inc.